Victory Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Victory Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,018	Closed	-$89K	–	2628
2022 Q3	$89K	Sell	11,018 -760	-6%	-$6.88K	﹤0.01%	2492
2022 Q2	$82K	Sell	11,778 -7	-0.1%	-$68	﹤0.01%	2484
2022 Q1	$140K	Sell	11,785 -393	-3%	-$6.17K	﹤0.01%	2467
2021 Q4	$267K	Sell	12,178 -81	-0.7%	-$1.99K	﹤0.01%	2415
2021 Q3	$331K	Sell	12,259 -131	-1%	-$3.74K	﹤0.01%	2351
2021 Q2	$298K	Sell	12,390 -253	-2%	-$7.75K	﹤0.01%	2418
2021 Q1	$548K	Buy	12,643 +2,643	+26%	+$117K	﹤0.01%	2163
2020 Q4	$415K	Buy	+10,000	New	+$413K	﹤0.01%	2160

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Victory Capital Management's FDMT Position: Q4 2022 in Review

Victory Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 11,018 shares — an estimated $89K sold.

Victory Capital Management first reported a position in FDMT in Q4 2020 and held it in 8 quarters. The position peaked at $548K in Q1 2021. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

Victory Capital Management reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
Victory Capital Management sold 11,018 4D Molecular Therapeutics shares in Q4 2022, an estimated $89K.
Victory Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 8 quarters.
Victory Capital Management's 4D Molecular Therapeutics position peaked at $548K in Q1 2021.
96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.